X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (132) 132
Publication (13) 13
Book / eBook (3) 3
Dissertation (2) 2
Book Chapter (1) 1
Book Review (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
Patent (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (54) 54
melanoma (54) 54
index medicus (51) 51
oncology (42) 42
female (31) 31
melanoma - drug therapy (29) 29
male (28) 28
aged (25) 25
ipilimumab (25) 25
cancer (22) 22
immunology (22) 22
metastatic melanoma (22) 22
metastasis (20) 20
middle aged (20) 20
immunotherapy (19) 19
medicine (18) 18
adult (17) 17
treatment outcome (17) 17
care and treatment (16) 16
melanoma - pathology (16) 16
research (16) 16
skin neoplasms - drug therapy (15) 15
melanoma - genetics (14) 14
drug therapy (13) 13
mutation (13) 13
skin neoplasms - pathology (12) 12
tumors (12) 12
vemurafenib (12) 12
aged, 80 and over (11) 11
open-label (11) 11
animals (10) 10
biochemistry, genetics and molecular biology (10) 10
biomarkers (10) 10
chemotherapy (10) 10
cutaneous melanoma (10) 10
health aspects (10) 10
medicine, research & experimental (10) 10
proto-oncogene proteins b-raf - genetics (10) 10
survival (10) 10
therapy (10) 10
antibodies, monoclonal - therapeutic use (9) 9
patients (9) 9
proto-oncogene proteins b-raf - antagonists & inhibitors (9) 9
analysis (8) 8
cancer research (8) 8
cancer therapies (8) 8
development and progression (8) 8
melanoma - immunology (8) 8
disease-free survival (7) 7
gene mutations (7) 7
malignant-melanoma (7) 7
medical research (7) 7
medicine & public health (7) 7
nivolumab (7) 7
poster presentation (7) 7
prognosis (7) 7
research article (7) 7
safety (7) 7
usage (7) 7
young adult (7) 7
adjuvant therapy (6) 6
antineoplastic agents - therapeutic use (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
dacarbazine (6) 6
follow-up studies (6) 6
lymphocytes (6) 6
melanoma - metabolism (6) 6
metastases (6) 6
multicenter (6) 6
neoplasm metastasis (6) 6
neoplasm staging (6) 6
phase-ii (6) 6
protein kinase inhibitors - therapeutic use (6) 6
risk factors (6) 6
skin neoplasms - genetics (6) 6
adolescent (5) 5
biochemistry & molecular biology (5) 5
biology (5) 5
blood (5) 5
braf (5) 5
clinical trials (5) 5
complications and side effects (5) 5
diagnosis (5) 5
disease progression (5) 5
genetic aspects (5) 5
immunohistochemistry (5) 5
kinases (5) 5
medicine, experimental (5) 5
melanoma - secondary (5) 5
mice (5) 5
oral presentation (5) 5
original research (5) 5
overall survival (5) 5
skin cancer (5) 5
antibodies, monoclonal - adverse effects (4) 4
apoptosis (4) 4
article (4) 4
best overall response (4) 4
case report (4) 4
combination therapy (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 879 - 886
Journal Article
Chemistry & Biodiversity, ISSN 1612-1872, 03/2012, Volume 9, Issue 3, pp. 589 - 597
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 7/2014, Volume 63, Issue 7, pp. 675 - 683
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 12/2017, Volume 18, Issue 6, pp. 745 - 754
The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway involved in the regulation of cellular proliferation and the survival... 
Pharmacotherapy | Medicine & Public Health | Pharmacology/Toxicology | Dermatology | DABRAFENIB | TRAMETINIB | KINASE | COBIMETINIB | OPEN-LABEL | BRAF | MUTATIONS | COMBINATION | CANCER | VEMURAFENIB | DERMATOLOGY | Cell proliferation | Usage | Care and treatment | Gene mutations | Melanoma | Genetic aspects | Research | Mitogen-activated protein kinases | Proteins | Cell division | Metastasis | Mutation | Kinases | Adenosine triphosphate | Cancer | Tumors | Apoptosis | Index Medicus
Journal Article
Journal Article
Melanoma Management, ISSN 2045-0885, 12/2017, Volume 4, Issue 4, pp. 175 - 178
At median follow-up of nearly 3years, 33-month OS and PFS rates with pembrolizumab compared with ipilimumab were 50 versus 39% and 31 versus 14%, respectively... 
pembrolizumab | anti-PD-1 antibodies | nivolumab | metastatic melanoma | Survival analysis | Chemotherapy | Melanoma | Response rates | Metastasis | Gene expression | Cancer therapies | Tumors
Journal Article
Journal Article
Journal Article